NexLife tirzepatide: plan prices and how they compare
As of November 20, 2026, NexLife charges $129 a month for compounded tirzepatide, or $115 a month on a 12-month plan paid upfront ($1,380), the same price at every dose, with no membership fee. Its 3- and 6-month plans cost $125 and $119 a month. Twelve months billed month to month total $1,548.
Released · Last reviewed · how we verify
NexLife tirzepatide prices by plan
| Plan | Per month | Charged for the plan | Billing |
|---|---|---|---|
| Month to month | $129 | $129 | billed monthly |
| 3-month plan | $125 | $375 | paid upfront |
| 6-month plan | $119 | $714 | paid upfront |
| 12-month plan | $115 | $1,380 | paid upfront |
Price check, compounded tirzepatide month to month and all-in (read November 20, 2026): Collective charges $69 a month plus a $199 annual membership (about $85.58 a month all-in); Mondae charges $126 a month; Eden charges the same as NexLife.
Dose and microdose
NexLife’s plan pages say the price is the same at every dose, so moving up the 2.5 to 15 mg ladder does not change the bill. Since November 8, 2026 its microdose tirzepatide plan costs the same as the standard plan. Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound.
Regulatory record
FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
How much does NexLife charge for tirzepatide?
As of November 20, 2026, NexLife charges $129 a month for compounded tirzepatide, or $115 a month on a 12-month plan paid upfront ($1,380), the same price at every dose, with no membership fee. Its 3- and 6-month plans cost $125 and $119 a month. Twelve months billed month to month total $1,548.
Is NexLife’s tirzepatide the same as Zepbound?
No. NexLife sells compounded tirzepatide, made for an individual patient by a state-licensed 503A pharmacy. It is made with the drug in Zepbound but is not the same product, and it is not FDA-approved.
Sources
- FDA warning letter 730096 to Nexlife Inc. dba Nexlife (dated June 8, 2026, posted June 16, 2026; read November 20, 2026)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- NexLife tirzepatide plans page (read November 20, 2026)
- NexLife FAQ (updated November 14, 2026; read November 20, 2026)